More Than 1.5 Billion Scale Layout Of Innovative Medicine: Yida "Health Industry Fund" Completed The Second Phase Of Raising

On March 2, the 21st century economic report learned that Yida capital's health achievement No.2 fund has completed the total amount of 1.557 billion yuan.

It is worth noting that the fund was closed only two months after the fund was raised. The LP participating in the fund investment not only includes government guided funds, state-owned capital and high net worth persons, but also many industrial investors. In addition, the core teams such as Shi Yunzhong and Xue Yi have further boosted investor confidence.

As for the rapid completion of the fund raising of health achievement No.2, Shi Yunzhong, the founding partner of Yida capital, said, "the structure of fund investors is undergoing obvious changes. When the health achievement No.1 fund was established, it was also Yida's entrepreneurial period. At that time, the investors who chose to invest in our fund were mainly financial investors, relying on the personal credit of the management team Gold's investors, industry investors account for a high proportion, relying on past performance and brand credit. "

"Many investors of No.2 fund are old investors of Yida health achievement series fund, which can be said to be long-term trust and unconditional trust." Shi Yunzhong revealed that the investment and operation performance of health achievement No.1 fund is excellent, which brings unique brand strength.

Behind the rapid completion of fund raising: fund one's accumulated performance, trust and methodology

It goes back five years. On May 19, 2015, "healthy China" rose to the eve of the national strategy. Jiangsu Yida achievement innovation and entrepreneurship Investment Fund (No.1 Fund) with a scale of 1 billion yuan was officially established. The fund is mainly invested in the digital diagnosis and treatment and other big health fields in the national science and technology achievements transformation project library, aiming to promote the transformation of major scientific and technological achievements in this field and promote the industrial transformation and upgrading.

As of January 2020, health achievement No.1 fund has invested in 28 science and technology-based small and medium-sized enterprises, 95% of the projects are led by Yida capital, which drives other institutions and social capital to jointly invest more than 2 billion yuan.

In terms of specific investment direction, according to the fund's attributes and team characteristics, health results No.1 fund adopted the investment strategy of "doing something but not doing something". At the beginning, it focused its firepower and resources on innovative drugs, high-end API and IVD diagnosis, saturated attack, and then further extended to high-end medical services, clinical needs and imported substitutes Generation opportunities for high-end medical devices these two new areas.

"Now, the fund has listed two projects of Kangtai medical and Shengxiang biology, three projects of Zhongyou medical and tianyiguan have been acquired with high premium, and more than ten projects are to be applied for IPO." "What's more, 44 scientific and technological achievements of these 28 small and medium-sized science and technology enterprises have been pushed back into the national science and technology achievements transformation project library," Shi Yunzhong said. This shows that through our investment, the enterprise's ability of scientific and technological research and achievement transformation is constantly iterating and upgrading. "

What the fund has accumulated is not only the past achievements and the trust of investors, but also increasingly professional team, rich practical experience and refined methodology.

As we all know, medical and health is an investment field with high degree of specialization. In order to enter this field, the team portfolio of Yida capital achievement fund has been positioned as "professional" from the beginning.

Xue Yi, a senior partner in charge of the investment team, is a medical professional with more than 10 years of fund management and investment experience in the fields of health care and intelligent manufacturing.

In addition to Xue Yi, 100% of the team members have academic and professional background in the big health industry, and more than 70% of the team members have more than 5 years' industrial background. They have been working together for at least 4 years.

"Driving investment by industry research and finding projects from industry" has become the core methodology of Yida health team. Seven years, 10000 hours, is the basic element of professional achievement. By studying the industry, getting familiar with the industry, expanding the source of cases along the industrial chain, demonstrating the project from the industrial trend and industrial dimension, and making friends with entrepreneurs and scientists, the compound interest effect of these actions is gathering more resources for Yida capital's medical and health investment.

Tactical upgrade: correct the direction with experience and lock the future with people

"We will continue to continue to do well in the past, including the judgment of the industry and the judgment of the enterprise." Introduction of Xue Yi.

In terms of investment strategy, No. 2 fund will lean towards earlier, newer and more scientific and technological enterprises.

"On the one hand, the outbreak of the epidemic and the global pandemic reflect that there are still many deficiencies in the process of responding to the epidemic, and there are still many difficulties and pain points to be tackled. On the other hand, Sino US relations and industrial chain reconstruction will have a significant impact on the world pattern, and independent innovation and import substitution in key scientific and technological fields are imminent. There is no end to science and technology, and there is no end to innovation. Our strategy of No.2 fund will continue to increase investment in science and technology, increase investment in import substitution and key industrial chain projects, and the investment stage will further move forward. " Xue Yi said.

In the specific field layout, the No.2 foundation increased its investment in the field of innovative drugs.

"The proportion of pure innovative drug enterprises in fund 1 is low, which is due to the fact that innovative drug enterprises generally have a long R & D cycle, large investment and difficult exit." Xue Yi said that with the continuous promotion of capital market reform, including the science and technology innovation board, the door has been opened for innovative pharmaceutical enterprises that have not yet made profits, which has brought strong incentives to innovative drug entrepreneurs, and also provided efficient exit channels for investment institutions.

"In the past two years, we have also seen that more and more overseas innovative pharmaceutical talents have returned home, bringing strong technical support to the innovative pharmaceutical industry. We believe that with the promotion of policies, talents and capital, domestic innovative drugs are expected to usher in a golden development period in the next few years."

In order to lock in this golden development period, we must increase investment. This investment is capital investment, technology investment, and even more human investment. According to Shi Yunzhong, the No.2 fund has been actively invested by the internal staff of Yida capital, which reflects the employees' confidence in the existing layout and investment future of Yida capital in the health industry. At the same time, the follow-up investment will greatly stimulate the enthusiasm of employees, and will enable the whole Yida team to have a more in-depth cognitive upgrade of the whole health industry, which is to determine the present, but also to lock in the future.

"After years of development, we have found that Yida capital is like a big tree that has grown into a preliminary stage. It has an increasingly prosperous ecology, which can help each unit in the ecosystem." Shi Yunzhong said that in the process of project investment and post investment management, Yida capital has given the enterprise a lot of resources. Some of these resources come from upstream and downstream industries invested by Yida, some from strategic partners, and even the fund investors behind Yida capital have been mobilized to provide value-added services for projects.

Through the normalization of post investment empowerment, CEO club, gift summit activities, etc., Yida capital has become a platform for linking resources from a pure capital side, and the industrial ecology of gp-lp-ceo is gradually booming.

It is understood that as of January 2021, Yida capital management team has managed 113.7 billion yuan of capital, invested and supported 957 start-up enterprises (including more than 100 enterprises in various subdivisions of the health industry), boosting 205 enterprises to enter the domestic and foreign capital markets.